Warfarin sensitivity and genetic polymorphisms: should pharmacokinetic screening be part of anticoagulant dosing decisions?
Baglin
Trevor P
TP
Addenbrooke's NHS Trust.
D000483:Alleles; D000925:Anticoagulants / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics* / Q000378:metabolism; D065729:Cytochrome P-450 CYP2C9; D016208:Databases, Factual; D004305:Dose-Response Relationship, Drug; D005838:Genotype; D006801:Humans; D008658:Inactivation, Metabolic / Q000235:genetics; D019934:International Normalized Ratio; D008403:Mass Screening; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic; D020641:Polymorphism, Single Nucleotide; D012107:Research Design; D012189:Retrospective Studies; D014859:Warfarin / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology
D000925:Anticoagulants; D014859:Warfarin; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases